Compass Bioinformatics
Compass Bioinformatics develops InheriNext, an AI-powered FDA-listed Class 1 SaMD platform that automates NGS variant interpretation for rare disease diagnostics, serving hospitals, medical centers, and research laboratories across Taiwan, Japan, and the United States.
- Company typePrivate
- Founded2015
- HeadquartersHsinchu, Taiwan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Compass Bioinformatics does
Compass Bioinformatics, founded in 2015 and headquartered in Hsinchu, Taiwan, develops InheriNext, an AI-powered web-based platform that automates NGS data interpretation for inherited disease diagnostics. The platform ingests FASTQ or VCF outputs, performs secondary analysis (variant calling including SNPs, Indels, CNVs, and structural variants), and ranks candidate disease-causing variants in 3–15 minutes using a proprietary phenotype-genotype ML algorithm benchmarked at 98.6% top-10 sensitivity. The product suite comprises four modules — Workflow Runner (secondary analysis), Phenotype Gene Prioritizer (ML-based variant ranking under ACMG/AMP guidelines), PhenoVarDB (cohort database in Beta), and Expert (domain-specific LLM chatbot in Beta) — and is registered with the US FDA as a Class 1 Software as a Medical Device.
The company monetizes through three pricing structures: annual SaMD subscriptions, per-report usage-based pricing for variable-volume institutions, and multi-year collaborative partnerships with research organizations. Go-to-market is hybrid: a four-stage enterprise sales motion (demo → trial → pilot license → custom integration) combined with product-led self-serve demo booking and significant event presence at major genetics conferences (ASHG, ACMG, JSHG, JSPG). Customers are predominantly hospitals, medical centers, and rare disease research institutes; the company reports deployments across 40+ institutes in Japan, 10,000+ cases analyzed worldwide, and named anchor customers including Japan's National Cerebral and Cardiovascular Center, National Center of Neurology and Psychiatry, and National Center for Child Health and Development, alongside Taipei Medical University Shuang-Ho Hospital.
Compass Bioinformatics operates through three regional hubs — Taiwan (HQ and R&D), Japan (wholly-owned subsidiary Compass株式会社 with dedicated General Manager Ping-Cheng Hsiung), and the United States (Austin, TX office) — and is led by CEO Frank Ong and CPO/co-founder Eric Tsai. In September 2025, BRIM Biotechnology (TWSE:6885) acquired a 42% strategic stake for up to NT$150 million (~$4.6M USD), positioning Compass as the AI-genomics arm of a clinical-stage biopharma. Additional strategic alliances include Genomenon (Mastermind FLEX Data integration), Revvity (genomics collaboration), TMU Digital Health Translational Alliance, and MCBIOS.
Compass Bioinformatics firmographics
Firmographics- Name
- Compass Bioinformatics
- Legal name
- Compass Bioinformatics Inc.
- Website
- https://compassbioinfo.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Compass Bioinformatics develops InheriNext, an AI-powered FDA-listed Class 1 SaMD platform that automates NGS variant interpretation for rare disease diagnostics, serving hospitals, medical centers, and research laboratories across Taiwan, Japan, and the United States.
- Ownership category
- akta.pro rank
Compass Bioinformatics industry classification
Industry- Product category
- Clinical Genomics Software
- NAICS
- Medical and Diagnostic Laboratories (6215), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Compass Bioinformatics is headquartered
LocationHeadquarters
- HQ city
- Hsinchu
- HQ country
- Taiwan
- HQ region
- Asia
Offices3 records
Markets served
Compass Bioinformatics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software as Medical Device (SaMD) Subscriptions: Annual license agreements for InheriNext platform access. US FDA listed Class 1 SaMD enabling clinical deployment. Subscription-based recurring revenue model.
- Per-Report Pricing: Usage-based pricing option where customers pay per genetic analysis report generated. Flexible model for institutions with variable testing volumes.
- Collaborative Partnerships: Custom partnership arrangements with academic institutions and research organizations including data integration and platform customization services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Annual License - Subscription model for ongoing platform access |
| Usage-based | Pay-as-you-go | Per-Report - Usage-based pricing for flexible testing volumes |
| Hybrid | Multi-year contract | Collaborative Partnership - Custom arrangements for research institutions |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
Compass Bioinformatics product offering
Product offeringCore offering
Compass Bioinformatics develops InheriNext®, an AI-powered next-generation sequencing (NGS) genomic analysis platform built to automate and accelerate rare disease diagnostics. The platform combines phenotype-driven gene prioritization, AI-based variant ranking, ACMG-compliant interpretation, and clinical reporting for clinical geneticists, molecular pathologists, and laboratory directors in hospital and reference lab settings, and holds US FDA Class 1 SaMD regulatory listing.
Product overview
Compass Bioinformatics offers a modular AI-powered genomic analysis platform called InheriNext, purpose-built for inherited disease diagnostics and clinical research. The platform is composed of a core AI-driven variant interpretation engine (InheriNext) plus four interchangeable modules: Workflow Runner handles secondary NGS analysis (FASTQ-to-VCF conversion); Phenotype Gene Prioritizer applies ML-based phenotype-genotype ranking to identify and rank causative variants; PhenoVarDB (in Beta) provides cohort database management and cross-patient variant matching; and Expert (in Beta) adds a conversational LLM interface for variant interpretation assistance. The platform is US FDA listed as a Class 1 Software as a Medical Device (SaMD) and is actively used in collaborations with medical centers across Taiwan, Japan, and the United States.
Differentiator
Problem solved
Functional benefit
Brands
- InheriNext®: AI-powered rare disease genetic diagnostic platform for NGS data interpretation, variant ranking, and clinical reporting
- InheriNext® Edge
Products and services
- InheriNext®
Quantifiable outcome
- 98.6% sensitivity for identifying causative variants within top 10 ranked variants
- +4 more outcomes
Companies that use Compass Bioinformatics
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
Compass Bioinformatics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability5 records
Feature7 records
Compass Bioinformatics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core, minor and flagship.
- GenomenoncoreStrategic partnership integrating Genomenon's Mastermind FLEX Data into InheriNext platform. Mastermind FLEX Data includes expertly curated gene and variant-level content with indexed variant-level information. The integration brings unparalleled genomic evidence to leading institutes across US, Japan, and beyond, elevating InheriNext's variant interpretation capabilities with continuous literature-based evidence updates.
- MidSouth Computational Biology and Bioinformatics Society (MCBIOS)minorAlliance partnership hosting educational webinars on variant analysis and AI in genomics discovery. MCBIOS advances bioinformatics and computational biology by connecting scientists, facilitating collaboration, promoting education, and supporting trainees in the field.
- Taipei Medical University Digital Health Translational (DHT) Industry-Academic AllianceflagshipThree-way partnership with TMU DHT Industry-Academic Alliance and Ministry of Health and Welfare Shuang-Ho Hospital Rare Disease Centre. Aimed at advancing precision medicine, genetic testing, and actionable clinical strategies for inherited diseases. Event held at TMU Biodesign Centre with over 50 leading medical professionals. Partnership to leverage big data and polygenic risk scores for clinical decision support systems.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Compass Bioinformatics competitors and assessment
Company assessmentBroad incumbents
- DNAnexus: Cloud-based genomic data platform used by clinical and research organizations for NGS analysis pipelines; broader infrastructure layer with overlapping clinical genomics capabilities.
- Tempus: Large AI-driven precision medicine platform with clinical NGS interpretation capabilities across oncology and rare disease, serving hospital systems with broader data analytics portfolio.
- Illumina (DRAGEN, BaseSpace): Sequencing giant offering DRAGEN secondary analysis and BaseSpace clinical interpretation apps, providing integrated NGS workflows that compete end-to-end with standalone platforms like InheriNext.
Direct peers
- SOPHiA Genetics: AI-driven clinical genomics platform for NGS data interpretation across rare disease, oncology, and hereditary disorders. Most direct competitor in multi-omics variant interpretation for hospitals and clinical labs.
- Congenica: Clinical genomic analysis platform for rare disease and inherited disorder variant interpretation, directly competing in the same hospital/lab market with AI-augmented workflows.
- BC Platforms: Genomic data analysis and interpretation platform serving hospitals, research institutions, and pharma with integrated NGS workflows and cohort tools.
- Fabric Genomics (Genomenon): AI-powered clinical NGS interpretation platform for rare disease diagnostics; notably now part of Genomenon, which is Compass's own data partner, making this both a peer and a closely-linked ecosystem player.
- Golden Helix: Genomic analysis software for clinical research and NGS variant annotation/interpretation, with comparable enterprise sales motion to hospital labs and research institutions.
- PierianDx (Elsevier): Clinical genomics interpretation platform for hereditary disease and oncology NGS, serving hospital systems and reference labs with variant interpretation workflows.
Others
- Genomenon: Genomic literature evidence partner (Mastermind FLEX) and parent of Fabric Genomics. Functions as both an ecosystem data supplier and a competitive platform via Fabric, making it a critical adjacent relationship.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Compass Bioinformatics social profiles
Digital presenceCompass Bioinformatics compliance and trust
Trust signalCompliance1 record
Compass Bioinformatics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Compass Bioinformatics leadership team
Management profileNumber of profiles
Profiles5 records
Compass Bioinformatics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Compass Bioinformatics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Compass Bioinformatics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Compass Bioinformatics
What does Compass Bioinformatics do?
Compass Bioinformatics develops InheriNext®, an AI-powered next-generation sequencing (NGS) genomic analysis platform built to automate and accelerate rare disease diagnostics. The platform combines phenotype-driven gene prioritization, AI-based variant ranking, ACMG-compliant interpretation, and clinical reporting for clinical geneticists, molecular pathologists, and laboratory directors in hospital and reference lab settings, and holds US FDA Class 1 SaMD regulatory listing.
Is Compass Bioinformatics a public or private company?
Compass Bioinformatics is a private company. It is classified as corporate owned and is currently operating.
When was Compass Bioinformatics founded?
Compass Bioinformatics was founded in 2015. It employs 11 to 50 people.
Where is Compass Bioinformatics based?
Compass Bioinformatics is headquartered in Hsinchu, Taiwan, in the Asia region.
How does Compass Bioinformatics make money?
Three revenue lines are on record. Software as Medical Device (SaMD) Subscriptions are the primary driver. The others are per-Report Pricing and collaborative Partnerships.
Who are Compass Bioinformatics's main competitors?
Broad incumbents on record are DNAnexus, Tempus and Illumina (DRAGEN, BaseSpace). Direct peers are SOPHiA Genetics, Congenica, BC Platforms, Fabric Genomics (Genomenon), Golden Helix and PierianDx (Elsevier). Genomenon is listed as an others.
Does Compass Bioinformatics have an API?
No public API is recorded for Compass Bioinformatics.
What industry is Compass Bioinformatics in?
Compass Bioinformatics's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 6215 and its SIC code is 8071.